Torrent Pharmaceuticals
Financials
Estimates*
INR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 78.9b | 84.2b | 94.6b | 105.6b | 120.3b | 136.0b | 151.6b |
% growth | 1 % | 7 % | 12 % | 12 % | 14 % | 13 % | 11 % |
EBITDA | 25.3b | 26.2b | 28.9b | 34.1b | 39.0b | 45.4b | 51.3b |
% EBITDA margin | 32 % | 31 % | 31 % | 32 % | 32 % | 33 % | 34 % |
Profit | 12.5b | 7.8b | 12.5b | 16.6b | 20.3b | 26.3b | 30.9b |
% profit margin | 16 % | 9 % | 13 % | 16 % | 17 % | 19 % | 20 % |
EV / revenue | 5.8x | 6.0x | 6.0x | 8.6x | 10.0x | 8.7x | 7.7x |
EV / EBITDA | 18.1x | 19.4x | 19.6x | 26.7x | 30.8x | 26.1x | 22.8x |
R&D budget | 252m | 387m | 313m | 247m | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | N/A | IPO | |
$40.0m | Post IPO Equity | ||
Total Funding | - |
Related Content
Recent News about Torrent Pharmaceuticals
EditTorrent Pharma, the flagship company of the Torrent Group, is a leading pharmaceutical company in India with a significant presence in over 50 countries. Founded in the early '70s by Late Shri U N Mehta, the company pioneered niche marketing in the Indian pharmaceuticals industry. Torrent Pharma specializes in therapeutic segments such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), women's healthcare (WHC), vitamins, minerals, nutritionals (VMN), and cosmo dermatology. The company also has a strong presence in diabetology, pain management, gynecology, oncology, and anti-infective segments.
Torrent Pharma's competitive advantage lies in its world-class manufacturing facilities, advanced research and development (R&D) capabilities, extensive domestic network, and widespread global presence. The company serves a diverse range of clients, including healthcare providers, hospitals, and pharmacies, operating in both domestic and international markets.
The business model of Torrent Pharma revolves around the development, manufacturing, and marketing of pharmaceutical products. The company generates revenue through the sale of its products in various therapeutic segments, leveraging its strong technical capabilities and international accreditations to maintain a competitive edge.
Keywords: cardiovascular, CNS, gastrointestinal, women's healthcare, niche marketing, global presence, R&D, manufacturing, oncology, anti-infective.